La Jolla Pharmaceutical Company Announces Development Programs for Lead ... MarketWatch (press release) The Company believes that GCS-100 is the most advanced galectin-3 inhibitor in development and plans to initially focus its development activities in two areas of great unmet medical need: chronic kidney disease and cancer. |
